返回 
加入收藏
我国5种上市血小板生成素受体激动剂的临床综合评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 我国5种上市血小板生成素受体激动剂的临床综合评价 |
| TITLE： | Clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists in China |
| 摘要： | 目的 对我国已上市的5种血小板生成素受体激动剂（TPO-RA）进行临床综合评价，为医疗机构药品遴选及药物治疗决策提供量化依据。方法收集注射用罗米司亭、艾曲泊帕乙醇胺片、海曲泊帕乙醇胺片、马来酸阿伐曲泊帕片与芦曲泊帕片的相关证据，依据《中国医疗机构药品评价与遴选快速指南（第二版）》，从有效性、安全性、药学特性、经济性和其他属性5个维度对上述5种TPO-RA的12个制剂进行量化评分并综合比较。结果12个制剂的综合评分范围为62.56～75.50分，多数制剂评分≥70分。以各通用名中评分最高的制剂为代表，5种TPO-RA的综合评分从高到低依次为芦曲泊帕片（75.50分）、艾曲泊帕乙醇胺片（75.10分）、马来酸阿伐曲泊帕片（70.40分）、注射用罗米司亭（63.93分）和海曲泊帕乙醇胺片（63.52分）。芦曲泊帕片在药学特性、安全性及经济性3个维度的评分相对较高，艾曲泊帕乙醇胺片在有效性及经济性维度评分较高，其余品种在各评价维度的评分存在差异。结论5种TPO-RA的总体临床价值较好，其中芦曲泊帕片和艾曲泊帕乙醇胺片综合评分更高，可作为医疗机构药品遴选及目录优化的重点考虑品种。 |
| ABSTRACT： | OBJECTIVE To conduct a clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists （TPO-RA） approved in China， providing quantitative evidence for drug selection and therapeutic decision-making in medical institutions. METHODS Relevant data on Romiplostim for injection， Eltrombopag olamine tablets， Herombopag olamine tablets， Avatrombopag maleate tablets， and Lusutrombopag tablets were collected. Based on the Chinese Rapid Guide for Drug Evaluation and Selection in Medical Institutions （Second Edition）， 12 formulations of these five TPO-RA were scored quantitatively and comparatively across five dimensions： pharmacological characteristics， efficacy， safety， cost-effectiveness， and other attributes. RESULTS The comprehensive scores of the 12 formulations ranged from 62.56 to 75.50 points， with most scoring ≥70 points. Using the highest-scoring formulation for each generic name as a representative， the overall rankings of the five TPO-RA were as follows： Lusutrombopag tablets （75.50 points）， Eltrombopag olamine tablets （75.10 points）， Avatrombopag maleate tablets （70.40 points）， Romiplostim for injection （63.93 points）， and Herombopag olamine tablets （63.52 points）. Lusutrombopag tablets scored relatively high in pharmacological characteristics， safety， and cost-effectiveness， while Eltrombopag olamine tablets performed well in efficacy and cost-effectiveness. The other formulations showed varying scores across evaluation dimensions. CONCLUSIONS The five TPO-RA demonstrate favorable overall clinical value， with Lusutrombopag tablets and Eltrombopag olamine tablets ranking higher in comprehensive scores， these two drugs should be prioritized in drug selection and formula optimization by medical institutions. |
| 期刊： | 2026年第37卷第02期 |
| 作者： | 张运瑾；吴晓蓉；黄志云；张美燕；张帆；刘洪涛 |
| AUTHORS： | ZHANG Yunjin，WU Xiaorong，HUANG Zhiyun，ZHANG Meiyan，ZHANG Fan，LIU Hongtao |
| 关键字： | 血小板生成素受体激动剂；艾曲泊帕乙醇胺片；芦曲泊帕片；药物遴选；综合评价 |
| KEYWORDS： | thrombopoietin receptor agonists； Eltrombopag olamine tablets； Lusutrombopag tablets； drug selection； |
| 阅读数： | 1 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
